binuclear copper(II) complex with S-isoamyl derivative of thiosalicylic acid

This binuclear copper(II) complex, frequently referred to as C3 or [Cu2(S-isopentyl-thiosal)4(H2O)2], is an investigational small molecule developed through a collaboration between researchers at the University of Kragujevac and the University of Belgrade. Designed as a potential alternative to traditional platinum-based chemotherapy, the complex targets DNA by binding to the minor groove of B-form DNA, which induces a local conformational transition to Z-form DNA. Beyond its genomic interactions, the compound significantly downregulates the expression of several pro-inflammatory and adhesion molecules, including pro-interleukin-1 beta (pro-IL-1β), tumor necrosis factor-alpha (TNF-α), intercellular adhesion molecule 1 (ICAM-1), and vascular cell adhesion molecule 1 (VCAM-1). Preclinical studies have demonstrated its selective cytotoxic activity against colon and lung carcinoma cells, with murine models showing significant reductions in primary tumor growth and metastasis to the lung and liver.

Other names

[Cu2(S-isoamyl-thiosal)4(H2O)2]binuclear copper(II) complex of S-isoamyl thiosalicylic acidbinuclear copper(II) complex of S-isopentyl-thiosalicylic acid